Item 8.01. Other Events.
On October 1, 2008, BioMed Realty Trust, Inc. (the "Company") entered into an underwriting agreement with UBS Securities LLC (the "Underwriter"), pursuant to which the Company agreed to issue and sell 7,500,000 shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), plus up to an additional 1,125,000 shares of Common Stock pursuant to the Underwriter's 30-day over-allotment option, at a price to the public of $24.93 per share. The Underwriter exercised its over-allotment option in full on October 1, 2008. The offering closed on October 6, 2008. Net proceeds from the offering of an aggregate of 8,625,000 shares were approximately $212.4 million after deducting underwriter discounts and commissions and estimated expenses. After the closing of the offering, the number of shares of Common Stock outstanding was 80,345,258.
The Company intends to use the net proceeds of the offering to repay a portion of the outstanding indebtedness under its $600.0 million unsecured line of credit and for other general corporate and working capital purposes. Item 9.01. Financial Statements and Exhibits.
(d) The following exhibits are filed herewith:

Exhibit Number Description of Exhibit 1.1 Underwriting Agreement, dated as of October 1, 2008, among the Company, BioMed Realty, L.P. and UBS Securities LLC 5.1 Opinion of Venable LLP 8.1 Opinion of Latham & Watkins LLP 23.1 Consent of Venable LLP (contained in the opinion filed as Exhibit 5.1 hereto) 23.2 Consent of Latham & Watkins LLP (contained in the opinion filed as Exhibit 8.1 hereto)

---

Table of Contents